Trial reportLasers in medical science2015
Effect of methylene blue-mediated photodynamic therapy for treatment of basal cell carcinoma.
Trial report in Lasers in medical science, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Methylene blue in anticancer photodynamic therapy: systematic review of preclinical studies.Frontiers in pharmacology · 2023Pooled it
- The effectiveness of fractional laser-assisted photodynamic therapy utilizing methylene blue for the treatment of keloids.Archives of dermatological research · 2025Article
- Topical methylene blue nanoformulation for the photodynamic therapy of acne vulgaris.Archives of dermatological research · 2023Article
- Nanotherapeutic Intervention in Photodynamic Therapy for Cancer.ACS omega · 2022Review
- Implications of photodynamic cancer therapy: an overview of PDT mechanisms basically and practically.Journal of the Egyptian National Cancer Institute · 2021Review
- Molecular interaction and cellular studies on combination photodynamic therapy with rutoside for melanoma A375 cancer cells: an in vitro study.Cancer cell international · 2020Article
- Photodynamic therapy for cancer: Role of natural products.Photodiagnosis and photodynamic therapy · 2019Review
- Superstructure-Dependent Loading of DNA Origami Nanostructures with a Groove-Binding Drug.ACS omega · 2018Article
- Pore forming channels as a drug delivery system for photodynamic therapy in cancer associated with nanoscintillators.Oncotarget · 2018Review
- Natural extracellular nanovesicles and photodynamic molecules: is there a future for drug delivery?Journal of enzyme inhibition and medicinal chemistry · 2017Review
- Dicyanomethylene Substituted Benzothiazole Squaraines: The Efficiency of Photodynamic Therapy In Vitro and In Vivo.EBioMedicine · 2017Article
- Complexing Methylene Blue with Phosphorus Dendrimers to Increase Photodynamic Activity.Molecules (Basel, Switzerland) · 2017Article
- Nanotechnology-Based Drug Delivery Systems for Photodynamic Therapy of Cancer: A Review.Molecules (Basel, Switzerland) · 2016Review
- Drug Carrier for Photodynamic Cancer Therapy.International journal of molecular sciences · 2015Review
- Coblation plus photodynamic therapy (PDT) for the treatment of juvenile onset laryngeal papillomatosis: case reports.World journal of surgical oncology · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Photodynamic therapy (PDT) is regarded as a treatment option for basal cell carcinoma (BCC). The aim of this study is to investigate the efficacy of methylene blue (MB)-based PDT in patients suffering from nodular or ulcerative BCCs. This study is a prospective clinical trial with a 6-months follow-up. The study setting is at the Dermatology Clinic at NILES, Cairo University, Egypt. Seventeen patients complaining of nodular BCC (nBCC) and three patients complaining of ulcerative BCC (uBCC) were taken as samples. Methylene blue, the photosensitizer, was prepared in two different formulas: liposomal-loaded MB (LMB) was prepared and formulated in hydrogel (MB 0.2%) to be used topically alone for treating BCCs <2 cm in diameter or to be combined with intralesional injection (ILI) of free MB 2% aqueous solution for treating BCCs ≥2 cm in diameter. A session was performed every 2 weeks until complete response (CR) of the lesion or for a maximum of six sessions. Clinical assessments of clinical improvement, dermatological photography, monthly follow-up visits for 6 months, and skin biopsy after 3 months of follow-up to confirm the response, recurrence, or both in cases in which the clinical evaluation was ambiguous. Seventeen patients of the 20 completed the study, 11 patients achieved CR with very good cosmetic outcome, photosensitizer tolerance, and minimal reported side effects. MB is a cheap promising alternative photosensitizer for PDT of nBCC.
Indexed as
Identifiers
25030404What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.